Australian pharmaceutical company Hatchtech has inked a deal worth up to $279 million with Indian giant Dr. Reddy's for the commercialisation of its innovative head lice treatment. Dr Reddy's Laboratories, a $US10.3 billion integrated pharmaceutical group listed in New York, will pay Hatchtech an undisclosed upfront fee, up to $85 million in pre-commercialisation milestone payments, and the remainder of the $279 million subject to sales-based milestones.